Vanda Pharmaceuticals Inc.VNDAEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapies for central nervous system disorders. Its key marketed products cover indications including sleep-wake cycle disturbances and schizophrenia, with core operations and primary sales markets concentrated in North America, catering to patient groups with significant unmet medical needs.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 14.50% | 8.3M | ▲ +2.70pp | 2024-01-23 |
| NOS. OF ABOVE PERSONS | 6.40% | 3.7M | — | 2024-02-13 |
| The Vanguard Group | 6.01% | 3.5M | — | 2024-02-13 |
| OF ABOVE PERSONS | 3.40% | 2.0M | — | 2024-02-09 |
| STATE STREET CORPORATION | 2.13% | 921.7M | — | 2024-01-22 |
Insider Transactions
Net 90d: −$2.58M · buys $0 / sells $2.58MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-22 | Duncan Charles Cliff | Director | Grant | 57.1K | $0.00 | $0 |
| 2026-03-02 | Polymeropoulos Mihael Hristos | President and CEO | Sell (open market) | 156.2K | $8.17 | $1.28M |
| 2026-03-02 | Gunther Birznieks | SVP, Business Development | Sell (open market) | 42.4K | $8.27 | $350.7K |
| 2026-03-02 | Joakim Wijkstrom | SVP, Chief Marketing Officer | Sell (open market) | 30.8K | $8.27 | $254.6K |
| 2026-03-02 | Timothy Williams | SVP & General Counsel | Sell (open market) | 42.4K | $8.27 | $350.8K |
| 2026-03-02 | Moran Kevin Patrick | SVP, CFO & Treasurer | Sell (open market) | 42.4K | $8.27 | $350.8K |
1–6 of 6